Immune checkpoint blockade: a common denominator approach to cancer therapy.
摘要：
The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.
展开
DOI：
10.1016/j.ccell.2015.03.001
被引量：
年份：
2015
Elsevier
Taylor & Francis
BMJ
万方医学
掌桥科研
查看更多
dx.doi.org
科研支点
(全网免费下载)
科研支点
Cell Press
NCBI
Europe PMC
NCBI
ResearchGate
onlinedigeditions.com
mct.aacrjournals.org
unife.it
(全网免费下载)
pdf-archive.com
(全网免费下载)
pubfacts.com
jhu.pure.elsevier.com
mysciencework.com
www.socolar.com
jacionline.org
onacademic.com
mendeley.com
core.ac.uk
(全网免费下载)
cghjournal.org
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
